BRIGHT MINDS BIOSCIENCES INC (DRUG) Fundamental Analysis & Valuation

NASDAQ:DRUG • CA10919W4056

Current stock price

89.16 USD
+0.48 (+0.54%)
At close:
89.16 USD
0 (0%)
After Hours:

This DRUG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DRUG Profitability Analysis

1.1 Basic Checks

  • DRUG had negative earnings in the past year.
  • In the past year DRUG has reported a negative cash flow from operations.
  • In the past 5 years DRUG always reported negative net income.
  • DRUG had a negative operating cash flow in each of the past 5 years.
DRUG Yearly Net Income VS EBIT VS OCF VS FCFDRUG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -21.84%, DRUG is in the better half of the industry, outperforming 73.64% of the companies in the same industry.
  • DRUG has a Return On Equity of -22.23%. This is amongst the best in the industry. DRUG outperforms 80.04% of its industry peers.
Industry RankSector Rank
ROA -21.84%
ROE -22.23%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRUG Yearly ROA, ROE, ROICDRUG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DRUG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRUG Yearly Profit, Operating, Gross MarginsDRUG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DRUG Health Analysis

2.1 Basic Checks

  • DRUG has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, DRUG has more shares outstanding
  • DRUG has a better debt/assets ratio than last year.
DRUG Yearly Shares OutstandingDRUG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2024 2025 2M 4M 6M
DRUG Yearly Total Debt VS Total AssetsDRUG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 445.00 indicates that DRUG is not in any danger for bankruptcy at the moment.
  • DRUG has a Altman-Z score of 445.00. This is amongst the best in the industry. DRUG outperforms 99.81% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that DRUG is not too dependend on debt financing.
  • The Debt to Equity ratio of DRUG (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 445
ROIC/WACCN/A
WACCN/A
DRUG Yearly LT Debt VS Equity VS FCFDRUG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

  • DRUG has a Current Ratio of 57.37. This indicates that DRUG is financially healthy and has no problem in meeting its short term obligations.
  • DRUG has a better Current ratio (57.37) than 99.22% of its industry peers.
  • A Quick Ratio of 57.37 indicates that DRUG has no problem at all paying its short term obligations.
  • DRUG's Quick ratio of 57.37 is amongst the best of the industry. DRUG outperforms 99.22% of its industry peers.
Industry RankSector Rank
Current Ratio 57.37
Quick Ratio 57.37
DRUG Yearly Current Assets VS Current LiabilitesDRUG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. DRUG Growth Analysis

3.1 Past

  • The earnings per share for DRUG have decreased strongly by -1037.00% in the last year.
EPS 1Y (TTM)-1037%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9848%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. DRUG Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DRUG. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRUG Price Earnings VS Forward Price EarningsDRUG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRUG Per share dataDRUG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DRUG Dividend Analysis

5.1 Amount

  • No dividends for DRUG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DRUG Fundamentals: All Metrics, Ratios and Statistics

BRIGHT MINDS BIOSCIENCES INC

NASDAQ:DRUG (4/24/2026, 5:31:19 PM)

After market: 89.16 0 (0%)

89.16

+0.48 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-13
Inst Owners62.94%
Inst Owner Change0%
Ins Owners11.73%
Ins Owner ChangeN/A
Market Cap872.88M
Revenue(TTM)N/A
Net Income(TTM)-19.84M
Analysts85.71
Price TargetN/A
Short Float %8.59%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.37
P/tB 13.37
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS6.67
TBVpS6.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -21.84%
ROE -22.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 57.37
Quick Ratio 57.37
Altman-Z 445
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1037%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9848%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-603.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-151.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.09%
OCF growth 3YN/A
OCF growth 5YN/A

BRIGHT MINDS BIOSCIENCES INC / DRUG Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRUG.


What is the valuation status of BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

ChartMill assigns a valuation rating of 0 / 10 to BRIGHT MINDS BIOSCIENCES INC (DRUG). This can be considered as Overvalued.


Can you provide the profitability details for BRIGHT MINDS BIOSCIENCES INC?

BRIGHT MINDS BIOSCIENCES INC (DRUG) has a profitability rating of 1 / 10.


Can you provide the financial health for DRUG stock?

The financial health rating of BRIGHT MINDS BIOSCIENCES INC (DRUG) is 6 / 10.